Quantitative Systematic Strategies LLC Akebia Therapeutics, Inc. Transaction History

Quantitative Systematic Strategies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 16, 2021	SELL	$2.35 - $3.88 $44,020 - $72,680	-18,732 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$2.83 - $4.2 $114,997 - $170,667	-40,635 Reduced 68.45%	18,732 $71,000
Q1 2021 May 06, 2021	BUY	$2.92 - $5.06 $173,351 - $300,397	59,367 New	59,367 $201,000
Q4 2020 Feb 09, 2021	SELL	$2.22 - $3.78 $36,399 - $61,976	-16,396 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$2.39 - $13.08 $30,020 - $164,297	-12,561 Reduced 43.38%	16,396 $41,000
Q2 2020 Aug 04, 2020	BUY	$6.67 - $13.58 $90,531 - $184,321	13,573 Added 88.23%	28,957 $393,000
Q1 2020 May 06, 2020	BUY	$4.1 - $10.24 $63,074 - $157,532	15,384 New	15,384 $117,000
Q1 2019 Apr 15, 2019	SELL	$5.41 - $8.73 $240,782 - $388,546	-44,507 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$5.39 - $9.15 $116,326 - $197,475	21,582 Added 94.14%	44,507 $246,000
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $170,562 - $244,151	22,925 New	22,925 $202,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Quantitative Systematic Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on Quantitative Systematic Strategies LLC with notifications on news.